TGA approves psilocybin, MDMA for treating depression and PTSD

TGA approves psilocybin, MDMA for treating depression and PTSD
By: 
Fecha de publicación: 
4 February 2023
0
Imagen principal: 

Australia´s medical regulator has passed the use of psychedelics to treat some mental health conditions, making the country one of the first in the world to officially recognize MDMA (ecstasy) and psilocybin as medicines.

According to the Therapeutic Goods Administration (TGA), as of July 1, authorized psychiatrists will be allowed to prescribe MDMA — the active ingredient in party drugs such as “ecstasy” or “molly” — to treat post-traumatic stress disorder (PTSD).

They will also be allowed to prescribe psilocybin, a compound found in psychotropic “magic” mushrooms, for treatment-resistant depression.

The TGA said the decision addressed the “lack of options” for people with some mental illnesses that did not respond to other treatments.

The TGA stressed that the drugs had only been approved for use under controlled medical settings by authorized psychiatrists.

The TGA said the decision to allow the treatment was made because for some patients, the benefits of being treated with these substances under a psychiatrist’s supervision outweighed the risks.

There are no TGA-approved medicines containing MDMA or psilocybin available in Australia, meaning authorised psychiatrists will need to supply patients with “unapproved” medicines containing those substances.

Add new comment

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.